ConSynance Therapeutics, Inc.
BioTech/Drugs - Rensselaer, NY, US
ConSynance Therapeutics, Inc. Employees
ConSynance Therapeutics, Inc. Senior Management
ConSynance Therapeutics, Inc. Details
ConSynance Therapeutics is a clinical-stage, biopharma company focused on rare central nervous system diseases. ConSynance's lead candidate, CSTI-500 (aka BMS-866949), is a Phase II ready, best-in-class Triple Monoamine Reuptake Inhibitor for Prader-Willi Syndrome, a rare genetic neurodevelopmental disorder. To learn about Prader-Willi Syndrome, please visit www.FPWR.org. Our 2nd candidate, CSTI-100, is a Phase II ready, first-in-class, Melanin-Concentrating-Hormone Receptor 1 ("MCHR1") inhibitor for PWS as well as for Non Alcoholic Steatohepatitis (NASH).
Website:
consynance.com
Employees:
5 - 9
HQ:
518-275-0176
Location:
Rensselaer, NY, US
Revenue:
Not Available
ConSynance Therapeutics, Inc. Technologies
Email Providers
Outlook
Load Balancers
Varnish
CMS
Wix
Hosting
Google Cloud Hosting
Other
Mobile Friendly